Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaozhun Huang

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Heliyon|February 3, 2025
Complete remission in an advanced hepatocellular carcinoma patient with AXIN1 mutation after systemic therapy: A case reportYihong Ran, Xiaozhun Huang, Xu Che, et al.
Future Oncology (London, England)|April 11, 2019
Is anatomical resection necessary for early hepatocellular carcinoma? A single institution retrospective experienceFengxiang Shi, Zheng Zhou, Xiaozhun Huang, et al.
Frontiers in Oncology|December 4, 2024
Laparoscopic liver resection versus radiofrequency ablation for hepatocellular carcinoma within Milan criteria: a meta-analysis and systematic reviewLin Xu, Zhenyu Lin, Dong Chen, et al.
Peerj|June 6, 2018
Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients in ChinaShuisheng Zhang, Xiaozhun Huang, Yuan Tian, et al.
Frontiers in Oncology|April 9, 2025
Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case reportXiaoqing Li, Suhua Ma, Qing She, et al.
Frontiers in Immunology|June 5, 2025
The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a meta-analysisWei Zhang, Zirong Liu, Hongjin Liu, et al.
Biochemical Pharmacology|September 21, 2025
UHRF1 ameliorates liver cirrhosis through suppressing macrophage M1 polarization by catalyzing HMGA2 promoter methylationRuixi Li, Qiang Tao, Jiandong Zha, et al.
Frontiers in Oncology|December 6, 2021
Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective StudyXiaozhun Huang, Lin Xu, Teng Ma, et al.
International Journal of Biological Macromolecules|December 24, 2024
Molecular and cellular mechanisms of PDAC progression based on RETN-CAP1-mediated macrophage-fibroblast crosstalk: Action of ITGB5 and ITGB1 recombinant proteinsGuangquan Zhang, Xiaozhun Huang, Ruixi Li, et al.
Frontiers in Oncology|October 17, 2022
Research progress of spontaneous ruptured hepatocellular carcinoma: Systematic review and meta-analysisChunling Wang, Xiaozhun Huang, Xiaofeng Lan, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Heliyon|February 3, 2025
Complete remission in an advanced hepatocellular carcinoma patient with AXIN1 mutation after systemic therapy: A case reportYihong Ran, Xiaozhun Huang, Xu Che, et al.
Future Oncology (London, England)|April 11, 2019
Is anatomical resection necessary for early hepatocellular carcinoma? A single institution retrospective experienceFengxiang Shi, Zheng Zhou, Xiaozhun Huang, et al.
Frontiers in Oncology|December 4, 2024
Laparoscopic liver resection versus radiofrequency ablation for hepatocellular carcinoma within Milan criteria: a meta-analysis and systematic reviewLin Xu, Zhenyu Lin, Dong Chen, et al.
Peerj|June 6, 2018
Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients in ChinaShuisheng Zhang, Xiaozhun Huang, Yuan Tian, et al.
Frontiers in Oncology|April 9, 2025
Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case reportXiaoqing Li, Suhua Ma, Qing She, et al.
Frontiers in Immunology|June 5, 2025
The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a meta-analysisWei Zhang, Zirong Liu, Hongjin Liu, et al.
Biochemical Pharmacology|September 21, 2025
UHRF1 ameliorates liver cirrhosis through suppressing macrophage M1 polarization by catalyzing HMGA2 promoter methylationRuixi Li, Qiang Tao, Jiandong Zha, et al.
Frontiers in Oncology|December 6, 2021
Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective StudyXiaozhun Huang, Lin Xu, Teng Ma, et al.
International Journal of Biological Macromolecules|December 24, 2024
Molecular and cellular mechanisms of PDAC progression based on RETN-CAP1-mediated macrophage-fibroblast crosstalk: Action of ITGB5 and ITGB1 recombinant proteinsGuangquan Zhang, Xiaozhun Huang, Ruixi Li, et al.
Frontiers in Oncology|October 17, 2022
Research progress of spontaneous ruptured hepatocellular carcinoma: Systematic review and meta-analysisChunling Wang, Xiaozhun Huang, Xiaofeng Lan, et al.
Pageof 2